Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for Patients in the 6th and 7th Decades of Life with AML or MDS Using Myeloablative, Reduced Toxicity IV Busulfan/Fludarabine (BuFlu) Conditioning Regimen

Autor: Alatrash, G., Andersson, B., Pelosini, M., Rondon, G., Qazilbash, M., Giralt, S., de Padua Silva, L., Hosing, C., Kebriaei, P., Zhang, W., Saliba, R., Champlin, R., de Lima, M.
Zdroj: In Biology of Blood and Marrow Transplantation February 2009 15(2) Supplement:106-106
Databáze: ScienceDirect
Externí odkaz: